Santhera Pharmaceuticals Holding AG Profit Margin

The latest profit margin for SPHDF is -64.76% as of June 2026. That compares with -1.54% in the prior-year period — down 4094.0% year over year. That is below the Healthcare sector average of 9.48%. Investors often review this figure alongside Santhera Pharmaceuticals Holding AG's historical trend and sector peers before judging valuation or financial health.

Over the past year, SPHDF's profit margin moved from -1.54% to -64.76% — a 4094.0% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Santhera Pharmaceuticals Holding AG's valuation or profitability profile.

Against Healthcare companies, SPHDF currently prints -64.76% for profit margin, while the sector average sits near 9.48%. That is roughly 783.0% below the sector mean. Large gaps often invite a closer look at Santhera Pharmaceuticals Holding AG's growth, margins, and balance sheet.

Profit Margin shows how effectively Santhera Pharmaceuticals Holding AG converts resources into returns. At -64.76%, SPHDF may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -1.54% in the prior-year period — down 4094.0% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting SPHDF's profit margin (-64.76%), review year-over-year change from -1.54%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.